
    
      Patients hospitalized for acute pancreatitis and admitted to an internal medicine team will
      be eligible for study. Patients enrolled will be blindly randomized to receive open-label
      pain management of standard of care or standard of care plus intravenous ketorolac. Patients
      will be enrolled between hour 24 and 48 of hospitalization.
    
  